Fractyl Health, Inc. Common Stock Earnings Recaps
Q3 2025
Nov 14, 2025
Fractyl Health achieved a significant milestone in Q3 2025 by demonstrating the efficacy of its Revita procedure in maintaining weight loss after the discontinuation of GLP-1 therapy, while also strengthening its financial position for upcoming clinical milestones.
Key takeaways
- Successfully reported randomized double-blind data indicating sustained weight loss in Revita-treated patients post-GLP-1 therapy, a critical advancement in obesity treatment.
- Clinical programs are ahead of schedule, with over 60% of patient randomizations for the pivotal REMAIN one cohort completed.
- Upcoming catalysts include six-month data from multiple cohorts and pivotal study results expected in 2026, positioning Revita for potential transformative impact in metabolic medicine.
- Real-world studies further validate Revita's efficacy, showing significant weight loss and reductions in HbA1c in patients with type 2 diabetes over extended follow-up periods.